CJC-1295 (No DAC)/Ipamorelin Blend 5/5mg

Product Category

Synergistic Growth Hormone Secretagogues & Pituitary Somatofactor Amplifiers

Action on the Human Body

The CJC-1295 No DAC / Ipamorelin Blend pairs two highly distinct growth hormone secretagogues to elicit an optimized pulsatile release of endogenous growth hormone (GH). CJC-1295 No DAC (Modified GRF 1-29) acts as a high-affinity GHRH (Growth Hormone Releasing Hormone) analog that binds directly to GHRH receptors on pituitary somatotropes, amplifying the specific amplitude of natural GH pulses. Ipamorelin acts as a highly selective Ghrelin receptor agonist, mimicking ghrelin signaling to suppress somatostatin (the hormone responsible for stopping GH release) while concurrently initiating a localized GH surge. Because Ipamorelin is completely selective, it does not provoke the unwanted elevation of cortisol, prolactin, or aldosterone often associated with lesser secretagogues. This dual-action mechanism drives rapid hepatic IGF-1 synthesis, shifts energy metabolism toward visceral fat burning, and accelerates muscle protein translation loops.

What to Expect if Consumed

Expect a clean, natural reduction in visceral body fat index, deep slow-wave sleep architecture enhancement, rapid cellular nitrogen retention, and noticeably faster muscular recovery parameters post-exertion.

Possible Therapy Combinations

Can be perfectly stacked with BPC-157 & TB-500 to drive accelerated structural injury healing, or paired with MOTS-C to establish an exceptional cellular energy and fat loss profile.

Molecular Formula & Chemical Composition

Composition: Balanced 5mg GHRH Modulator and 5mg Selective Ghrelin Receptor Agonist Lyophilized Complex. Purity: >99% Pure HPLC Analytical Grade Mass.

WARNING: This peptide compound must be handled and utilized exclusively under very high, correct professional and qualified medical supervision. Misuse can lead to unintended biological variations.

Scientific References

1. Raun, K., et al. (1998). ‘Ipamorelin, the first selective growth hormone secretagogue.’ European Journal of Endocrinology.
2. Teichman, S. L., et al. (2006). ‘Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting GHRH analog.’ Journal of Clinical Endocrinology & Metabolism.